Pharma channel feed

Lil­ly's di­a­betes and obe­si­ty leader to re­tire in broad­er lead­er­ship shuf­fle as CSO Dan Skovron­sky takes on im­munol­o­gy role

Last year
People

We­govy, Ozem­pic ex­clu­siv­i­ty chal­lenges de­nied by US patent ap­peal board

Last year

FDA clears No­vavax’s fall boost­er for Covid-19, weeks af­ter mR­NA vac­cine boost­ers 

Last year
FDA+
Coronavirus

Mar­ket­ingRx roundup: Phar­mas nab ‘green­est’ awards; Gilead spon­sors ESG ex­ec­u­tive con­fer­ence

Last year
Marketing

Bris­tol My­ers notch­es di­ver­si­ty gains af­ter re­vamp­ing its clin­i­cal tri­al lo­ca­tion strat­e­gy

Last year
Marketing

Ex­sci­en­tia ends can­cer study as it fo­cus­es on oth­er tri­als of AI-dri­ven drug can­di­dates

Last year
R&D
AI

Eli Lil­ly to buy ra­dio­phar­ma com­pa­ny Point Bio­phar­ma for $1.4B as PhI­II read­out looms

Last year
Deals

As­traZeneca pays out $425M to set­tle lit­i­ga­tion over Prilosec and Nex­i­um but ad­mits no wrong­do­ing

Last year
Law

Take­da to pull lung can­cer drug Exkiv­i­ty world­wide af­ter con­fir­ma­to­ry tri­al dis­ap­point­ment

Last year

Hori­zon de­buts lat­est thy­roid eye dis­ease TV com­mer­cials as Am­gen merg­er nears

Last year
Marketing

No­vo Nordisk se­cures FDA ap­proval of RNAi ther­a­py from $3.3B Dicer­na takeover

Last year
FDA+

Bio­gen nabs FDA ap­proval for its biosim­i­lar of arthri­tis and Covid-19 drug Actem­ra

Last year
FDA+

Fed­er­al judge de­nies Cham­ber of Com­merce's ef­fort to block IRA's Medicare drug price ne­go­ti­a­tion pro­vi­sions

Last year
FDA+

All phar­ma com­pa­nies in the first round of Medicare price ne­go­ti­a­tions agree to par­tic­i­pate

Last year

In­fin­i­ty Phar­ma­ceu­ti­cals files for bank­rupt­cy af­ter lay­offs, scrapped merg­er with MEI Phar­ma

Last year

Sen. Bill Cas­sidy calls on hos­pi­tals to pro­vide more in­for­ma­tion on how they use 340B funds

Last year

MEI Phar­ma push­es back on ac­tivist in­vestors af­ter failed merg­er with In­fin­i­ty

Last year

Fed­er­al gov­ern­ment shut­down watch: FDA and in­dus­try prep for like­ly clo­sure Oct. 1

Last year
FDA+

PBM re­forms: Sen­ate Fi­nance Com­mit­tee lead­ers in­tro­duce an­oth­er bi­par­ti­san bill

Last year

CDER tweaks Ozem­pic’s post-mar­ket­ing la­bel to in­clude risk for GI dis­or­der

Last year

Mer­ck to par­tic­i­pate in Medicare ne­go­ti­a­tions process 'un­der protest,' fol­low­ing at least three oth­ers

Last year

GSK's Vi­iV to lean on long-act­ing HIV port­fo­lio ahead of do­lute­gravir patent ex­pi­ra­tion

Last year

Bris­tol My­ers teams with so­cial me­dia in­flu­encer and singer to spark rare heart con­di­tion aware­ness

Last year
Marketing

Boehringer agrees to com­ply with CM­S' price ne­go­ti­a­tions over block­buster Jar­diance

Last year
First page Previous page 99100101102103104105 Next page Last page
A service from the Financial Times